Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the drug ...
My niece was diagnosed with birdshot chorioretinopathy.
In a report released on March 30, Nicolas Pauillac from Kepler Capital maintained a Hold rating on Sanofi, with a price target of €85.00. The company’s shares closed yesterday at €81.90. According to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results